Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer
Phase II Study of Nimotuzumab (TheraCim-hR3) Concurrent With Cisplatin/Radiotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Sponsor: Innogene Kalbiotech Pte. Ltd
A PHASE2 clinical study on Head and Neck Cancer, this trial is completed. The trial is conducted by Innogene Kalbiotech Pte. Ltd and has accumulated 10 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Oct 2021 — Mar 2023 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2
▶ Show 5 earlier versions
-
Jun 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Oct 2018 — Jun 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Apr 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Innogene Kalbiotech Pte. Ltd
- National Cancer Centre, Singapore
For direct contact, visit the study record on ClinicalTrials.gov .